InflaRx N.V. (IFRX)

NASDAQ
3.89
-0.09(-2.26%)
After Hours
4.15
+0.26(+6.68%)
- Real-time Data
  • Volume:
    274,141
  • Bid/Ask
    4.00/4.15
  • Day's Range
    3.82 - 4.04

IFRX Overview

Prev. Close
3.89
Day's Range
3.82 - 4.04
Revenue
0
Open
3.97
52 wk Range
2.52 - 9.68
EPS
-1.75
Volume
274,141
Market Cap
168.16M
Dividend (Yield)
N/A (N/A)
Average Volume (3m)
402,039
P/E Ratio
N/A
Beta
0.52
1-Year Change
-12.98%
Shares Outstanding
43,228,415
Next Earnings Date
31 Mar 2021
What is your sentiment on InflaRx N.V.?
or
Market is currently closed. Voting is open during market hours.

InflaRx N.V. News

  • InflaRx launches stock offering
    • BySeeking Alpha-

    InflaRx (IFRX)traded 9.9% down after hourson commencing an underwritten public offering of shares; for each common share purchased, an investor will also receive a warrant to...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellSellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

InflaRx N.V. Company Profile

InflaRx N.V. Company Profile

Employees
45

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.